Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Joins the Russell 3000® and Russell 2000® Indexes
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer